EDSA

Over the past six months, Edesa Biotech's stock price has been significantly impacted by several clinical trial developments and financial reports. On February 24, 2026, shares surged 77% after positive results from a Phase 3 study of paridiprubart (EB05). On December 12, 2025, the stock declined 16.09% following the company's report of its Fiscal Year 2025 results. On February 13, 2026, the stock showed a slight increase of 0.49% after Edesa Biotech reported its Fiscal 1st Quarter 2026 results. On March 26, 2026, the stock decreased by 10.81% after Edesa Biotech announced it was advancing its vitiligo program. On March 31, 2026, Edesa Biotech was invited for an oral showcase at the Respiratory Innovation Summit, leading to a 6.12% increase in stock price. As of May 8, 2026, the company's stock price was $16.30 per share, representing a significant increase of 691.26% from May 9, 2025.